270 related articles for article (PubMed ID: 21328566)
1. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens.
Haynes CM; Sangoi AR; Pai RK
Cancer Cytopathol; 2011 Jun; 119(3):193-201. PubMed ID: 21328566
[TBL] [Abstract][Full Text] [Related]
2. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.
Sangoi AR; Ohgami RS; Pai RK; Beck AH; McKenney JK; Pai RK
Mod Pathol; 2011 Mar; 24(3):412-24. PubMed ID: 20890270
[TBL] [Abstract][Full Text] [Related]
3. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
Long KB; Srivastava A; Hirsch MS; Hornick JL
Am J Surg Pathol; 2010 May; 34(5):723-9. PubMed ID: 20414099
[TBL] [Abstract][Full Text] [Related]
4. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin.
Koo J; Mertens RB; Mirocha JM; Wang HL; Dhall D
Mod Pathol; 2012 Jun; 25(6):893-901. PubMed ID: 22388755
[TBL] [Abstract][Full Text] [Related]
5. Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.
Lai JP; Mertens RB; Mirocha J; Koo J; Venturina M; Chung F; Mendez AB; Kahn M; Dhall D
Endocr Pathol; 2015 Mar; 26(1):54-62. PubMed ID: 25433656
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors.
Lorenzo PI; Jimenez Moreno CM; Delgado I; Cobo-Vuilleumier N; Meier R; Gomez-Izquierdo L; Berney T; Garcia-Carbonero R; Rojas A; Gauthier BR
Histochem Cell Biol; 2011 Nov; 136(5):595-607. PubMed ID: 21932072
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
[TBL] [Abstract][Full Text] [Related]
8. ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin.
Agaimy A; Erlenbach-Wünsch K; Konukiewitz B; Schmitt AM; Rieker RJ; Vieth M; Kiesewetter F; Hartmann A; Zamboni G; Perren A; Klöppel G
Mod Pathol; 2013 Jul; 26(7):995-1003. PubMed ID: 23503646
[TBL] [Abstract][Full Text] [Related]
9. PAX8 mouse monoclonal antibody [BC12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with b cells and tumors of pancreatic origin.
Tacha D; Qi W; Zhou D; Bremer R; Cheng L
Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):59-63. PubMed ID: 22595948
[TBL] [Abstract][Full Text] [Related]
10. The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin.
Koo J; Zhou X; Moschiano E; De Peralta-Venturina M; Mertens RB; Dhall D
Endocr Pathol; 2013 Dec; 24(4):184-90. PubMed ID: 24037217
[TBL] [Abstract][Full Text] [Related]
11. Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1.
Weissferdt A; Tang X; Wistuba II; Moran CA
Mod Pathol; 2013 Dec; 26(12):1554-60. PubMed ID: 23787439
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive analysis of PAX8 expression in human epithelial tumors.
Laury AR; Perets R; Piao H; Krane JF; Barletta JA; French C; Chirieac LR; Lis R; Loda M; Hornick JL; Drapkin R; Hirsch MS
Am J Surg Pathol; 2011 Jun; 35(6):816-26. PubMed ID: 21552115
[TBL] [Abstract][Full Text] [Related]
13. The Diagnostic Utility of PAX8 for Neuroendocrine Tumors: An Immunohistochemical Reappraisal.
Liau JY; Tsai JH; Jeng YM; Kuo KT; Huang HY; Liang CW; Yang CY
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):57-63. PubMed ID: 25710581
[TBL] [Abstract][Full Text] [Related]
14. Value of PAX 8 immunostaining in tumor diagnosis: a review and update.
Ordóñez NG
Adv Anat Pathol; 2012 May; 19(3):140-51. PubMed ID: 22498579
[TBL] [Abstract][Full Text] [Related]
15. Decreased UCHL1 expression as a cytologic biomarker for aggressive behavior in pancreatic neuroendocrine tumors.
Moore MD; Finnerty B; Gray KD; Hoda R; Liu YF; Soong L; Beninato T; Rao R; Zarnegar R; Fahey TJ
Surgery; 2018 Jan; 163(1):226-231. PubMed ID: 29150024
[TBL] [Abstract][Full Text] [Related]
16. Napsin A expression in anaplastic, poorly differentiated, and micropapillary pattern thyroid carcinomas.
Chernock RD; El-Mofty SK; Becker N; Lewis JS
Am J Surg Pathol; 2013 Aug; 37(8):1215-22. PubMed ID: 23681073
[TBL] [Abstract][Full Text] [Related]
17. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
McKnight R; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
[TBL] [Abstract][Full Text] [Related]
18. Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study.
Sigel CS; Krauss Silva VW; Reid MD; Chhieng D; Basturk O; Sigel KM; Daniel TD; Klimstra DS; Tang LH
Cancer Cytopathol; 2018 Jan; 126(1):44-53. PubMed ID: 29044913
[TBL] [Abstract][Full Text] [Related]
19. L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma.
Kaifi JT; Zinnkann U; Yekebas EF; Schurr PG; Reichelt U; Wachowiak R; Fiegel HC; Petri S; Schachner M; Izbicki JR
World J Gastroenterol; 2006 Jan; 12(1):94-8. PubMed ID: 16440424
[TBL] [Abstract][Full Text] [Related]
20. Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.
Sigel CS; Guo H; Sigel KM; Zhang M; Rekhtman N; Lin O; Klimstra DS; Jungbluth AA; Tang LK
Cancer Cytopathol; 2017 Mar; 125(3):188-196. PubMed ID: 28094897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]